查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
多系統萎縮市場：現況分析與預測（2023-2030）
市場調查報告書
商品編碼
1346779

多系統萎縮市場：現況分析與預測（2023-2030）

Multiple System Atrophy Market: Current Analysis and Forecast (2023-2030)
出版日期: | 出版商: UnivDatos Market Insights Pvt Ltd | 英文 148 Pages | 商品交期: 最快1-2個工作天內

價格
簡介目錄

由於 50-55 歲及以上老年人口不斷增加，因此多系統萎縮市場預計在預測期內將以 4% 的複合年增長率增長。 老年人口的增加是全球多系統萎縮市場的驅動因素。 根據世界衛生組織(WHO)預測，到2030年，60歲以上人口的比例將增加至14億，到2050年將增加至21億。 中國和印度是世界上人口老化程度最高的國家。

依類型，市場分為帕金森型和小腦型。 到 2022 年，小腦型將佔據壓倒性的市場。 MSA-C（小腦）被鑑定為小腦性共濟失調。 與 MSA-P 相比，MSA-C 的疾病進展較慢，患者存活期相對較長。 到 2020 年，MSA-C 的發生率和盛行率估計為每 10 萬人 3.4 至 4.9 例。 因此，小腦亞型盛行率的增加是推動此領域發展的主要因素之一。

依診斷方式分為磁振造影（MRI）、正子斷層掃描（PET）、單光子發射斷層掃描（SPECT）、傾斜台檢查等。 近年來，正子斷層掃描（PET）在市場上比其他任何診斷方法都更受歡迎。 PET 診斷可用於監測大腦特定區域的代謝功能。 2023 年，PET 檢測在多系統萎縮市場中佔據主導地位。 例如，2020年10月，西門子推出了一款名為Biograph Vision Quadra的新型PET掃描器。

依年齡分為兒童、成人、老人。 多系統萎縮在 50 至 55 歲及以上的老年人中變得越來越普遍。 老齡化人口的成長正在推動市場。 預計在預測期內老年人口將顯著增加。 根據世界衛生組織的報告，老年人口預計將從 2020 年的 10 億增加一倍，達到 2050 年的 21 億。

依最終用途，市場分為醫院、門診手術中心等。 2022年，醫院在多系統萎縮市場中佔有很大份額。 這是因為多系統萎縮的診斷測試通常在醫院進行，因為大多數診斷設備在醫院都有。 除此之外，醫院數量的增加也推動了這一領域的成長。 例如，根據美國醫院協會的數據，截至2022年10月，美國約有6,093家醫院，其中包括非營利組織以及州和地方政府營運的社區醫院。

為了更了解潔牙片產業的市場介紹，將市場分為北美（美國、加拿大和北美其他地區）、歐洲（德國、英國、法國、西班牙、義大利和其他地區）歐洲）、亞太地區（中國、日本、印度、亞太地區其他地區）以及世界其他國家。 由於神經遺傳疾病的增加，2022 年北美將擁有最高的多系統萎縮市場。 預計在預測期內，多系統萎縮將以顯著的複合年增長率成長。 根據美國國家神經疾病和中風研究所的數據，這種疾病影響著 15,000 至 50,000 名美國人，無論膚色或種族如何。 此外，該國研發活動的增加也促進了預測期內的市場成長。 預計在預測期內，該地區對多系統萎縮治療的需求將會增加。 例如，最近（2023年5月）Alterity Therapeutics在美國對其治療多系統萎縮症的藥物ATH434進行了2期試驗。

目錄

第 1 章市場介紹

  • 市場定義
  • 主要目標
  • 利害關係人
  • 限制

第 2 章研究方法或假設

  • 調查過程
  • 調查方法
  • 受訪者簡介

第 3 章市場總結

第 4 章執行摘要

第 5 章新型冠狀病毒感染（COVID-19）對全球多系統萎縮市場的影響

第 6 章 2020-2030 年全球多系統萎縮市場收入

第 7 章按類型劃分的市場洞察

  • 帕金森氏症
  • 小腦

第 8 章診斷市場洞察

  • 磁振造影 (MRI)
  • 正子斷層掃描 (PET)
  • 單光子發射電腦斷層掃描 (SPECT)
  • 傾斜台測試
  • 其他

第 9 章按年齡劃分的市場洞察

  • 兒童
  • 成人
  • 老人

第 10 章最終使用者的市場洞察

  • 醫院
  • 門診手術中心
  • 其他

第 11 章按地區劃分的市場洞察

  • 北美
    • 美國
    • 加拿大
    • 其他北美地區
  • 歐洲
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙
    • 其他歐洲地區
  • 亞太地區
    • 中國
    • 日本
    • 印度
    • 其他亞太地區
  • 世界其他地區

第 12 章多系統萎縮市場動態

  • 市場促進因素
  • 市場挑戰
  • 影響分析

第 13 章多系統萎縮市場機會

第 14 章多系統萎縮市場趨勢

第 15 章需求方與供給方分析

  • 需求方分析
  • 供給面分析

第 16 章價值鏈分析

第 17 章競爭場景

  • 波特五力分析
  • 競爭狀況

第 18 章公司簡介

  • Biohaven, Ltd.
  • Theravance Biopharma
  • Sumitomo Dainippon Pharma Co., Ltd.
  • Alterity Therapeutics
  • AstraZeneca
  • Biogen
  • Merck & Co., Inc.
  • Neuropore Therapies, Inc.
  • WaveBreak Therapeutics
  • Newron Pharmaceuticals SPA.

第 19 章免責聲明

簡介目錄
Product Code: UMHE212240

Multiple system atrophy is a very rare neurodegenerative disorder of nervous system where nerve cells or brain cells go through a gradual damage. It affects all activities controlled by brain and severely impacts movement, balance and autonomous nervous system. Currently, there is no specific diagnosis test or treatment available in the market for the identification or management of multiple system atrophy. This is one of the major factor driving the market during the forecast period. Several other factors, increase in geriatric population, including government initiatives for research and development activities, promising product pipeline and technological advancements are driving the growth of the market during the forecast period.

The Multiple System Atrophy Market is expected to grow at a strong CAGR of 4% during the forecast period owing to increase in geriatric population, as this disorder is more prevalent in age 50-55 years and above. Rising geriatric population is a propelling factor in Multiple System Atrophy market globally. According to World Health Organization (WHO), share of people aged above 60 will raise to 1.4 billion by 2030 while this share will increase to 2.1 billion by 2050 which would be more than double of the share of geriatric population in year 2020 i.e., 1 billion. China and India are leading in the list of countries with highest geriatric population in the world.

Based on the types, the market is bifurcated into parkinsonian and cerebellar. The cerebellar held dominant share of the market in 2022. MSA-C (cerebellar) is identified with cerebellar ataxia. MSA-C exhibits slower progression of the disease and patients survive relatively a longer life span as compared to MSA-P. The incidence and prevalence of MSA-C is 3.4 to 4.9 cases per 100,000 population as estimated in the year 2020. Thus, the increase in the prevalence of cerebellar subtype is one of the major factor driving the segment growth.

By diagnosis, the market is categorized into magnetic resonance imaging (MRI), positron emission tomography (PET), single photon emission computed tomography (SPECT), tilt table test and others. Positron emisssion tomography (PET) has shown more prevalence over the market in recent years than other diagnostic methods. PET diagnostics can be used to monitor metabolic functions in particular part of brain. PET scan dominated Multiple System Atrophy market in year 2023. For instance, in October 2020, Siemens launched a new PET scanner, named Biograph Vision Quadra, with a 106-cm axial PET field of view which facilitates whole-body imaging.

Based on age, the market is differentiated into Pediatric, Adults and Geriatric. Multiple system atrophy has shown prevalence in people aged 50-55 and above. The rising geriatric population has turned out to be a driving factor in the market. The geriatric population is expected to rise considerably in the forecast period. WHO reports suggest that the geriatric population is expected to double (2.1 billion) in year 2050 as compared to the geriatric population (1 billion) in year 2020.

Based on end use, the market is segmented into hospitals, ambulatory surgical centers and others. The hospitals held the significant share in the Multiple System Atrophy Market in 2022. This is due to higher diagnostic tests of multiple system atrophy in hospitals as most diagnostic equipments are available in hospital settings. Apart from this, the growing number of hospitals is also propelling the segmental growth. For instance, according to the American Hospital Association, there were about 6,093 hospitals in the U.S. in October 2022, of which comprises community hospitals run by non-profit organizations as well as by state and local governments.

For a better understanding of the market adoption of the dental clensing tablet industry, the market is analyzed based on its worldwide presence in the countries such as North America (U.S., Canada, Rest of North America), Europe (Germany, U.K., France, Spain, Italy, Rest of Europe), Asia-Pacific (China, Japan, India, Rest of Asia-Pacific), Rest of World. North America has reported highest market share in multiple system atrophy market in the year 2022 owing to rising neurogenetic disorders in the country. Multiple system atrophy is anticipated to grow at a substantial CAGR during the forecast period. According to National Institute of Neurological Disorders and Stroke, it affects significantly 15,000 to 50,000 americans irrespective of colour or racial groups. Further, the rise in research and development activities in the country is also driving the market growth during the forecast period. Over the projection period, this is expected to increase demand for multiple system atrophy treatment in this region. For instance, recently in May,2023, Alterity Therapeutics consucted Phase 2 trials for drug ATH434 against multiple system atrophy in U.S.

Some of the major players operating in the market include: Biohaven, Ltd.; Theravance Biopharma; Sumitomo Dainippon Pharma Co., Ltd.; Alterity Therapeutics; AstraZeneca; Biogen; Merck & Co., Inc.; Neuropore Therapies, Inc.; WaveBreak Therapeutics; Newron Pharmaceuticals SPA.

TABLE OF CONTENTS

1 MARKET INTRODUCTION

  • 1.1. Market Definitions
  • 1.2. Main Objective
  • 1.3. Stakeholders
  • 1.4. Limitation

2 RESEARCH METHODOLOGY OR ASSUMPTION

  • 2.1. Research Process of the Multiple System Atrophy Market
  • 2.2. Research Methodology of the Multiple System Atrophy Market
  • 2.3. Respondent Profile

3 MARKET SYNOPSIS

4 EXECUTIVE SUMMARY

5 GLOBAL MULTIPLE SYSTEM ATROPHY MARKET COVID-19 IMPACT

6 GLOBAL MULTIPLE SYSTEM ATROPHY MARKET REVENUE, 2020-2030F

7 MARKET INSIGHTS BY TYPES

  • 7.1. Parkinsonian
  • 7.2. Cerebellar

8 MARKET INSIGHTS BY DIAGNOSIS

  • 8.1. Magnetic Resonance Imaging (MRI)
  • 8.2. Positron Emission Tomography (PET)
  • 8.3. Single Photon Emission Computed Tomography (SPECT)
  • 8.4. Tilt Table Test
  • 8.5. Others

9 MARKET INSIGHTS BY AGE

  • 9.1. Pediatric
  • 9.2. Adults
  • 9.3. Geriatric

10 MARKET INSIGHTS BY END USER

  • 10.1. Hospitals
  • 10.2. Ambulatory Surgical Centers
  • 10.3. Others

11 MARKET INSIGHTS BY REGION

  • 11.1. North America
    • 11.1.1. United States
    • 11.1.2. Canada
    • 11.1.3. Rest of North America
  • 11.2. Europe
    • 11.2.1. Germany
    • 11.2.2. France
    • 11.2.3. U.K.
    • 11.2.4. Italy
    • 11.2.5. Spain
    • 11.2.6. Rest of Europe
  • 11.3. Asia Pacific
    • 11.3.1. China
    • 11.3.2. Japan
    • 11.3.3. India
    • 11.3.4. Rest of Asia Pacific
  • 11.4. Rest of World

12 MULTIPLE SYSTEM ATROPHY MARKET DYNAMICS

  • 12.1. Market Drivers
  • 12.2. Market Challenges
  • 12.3. Impact Analysis

13 MULTIPLE SYSTEM ATROPHY MARKET OPPORTUNITIES

14 MULTIPLE SYSTEM ATROPHY MARKET TRENDS

15 DEMAND AND SUPPLY-SIDE ANALYSIS

  • 15.1. Demand Side Analysis
  • 15.2. Supply Side Analysis

16 VALUE CHAIN ANALYSIS

17 COMPETITIVE SCENARIO

  • 17.1. Porter's Five Forces Analysis
  • 17.2. Competitive Landscape

18 COMPANY PROFILED

  • 18.1. Biohaven, Ltd.
  • 18.2. Theravance Biopharma
  • 18.3. Sumitomo Dainippon Pharma Co., Ltd.
  • 18.4. Alterity Therapeutics
  • 18.5. AstraZeneca
  • 18.6. Biogen
  • 18.7. Merck & Co., Inc.
  • 18.8. Neuropore Therapies, Inc.
  • 18.9. WaveBreak Therapeutics
  • 18.10. Newron Pharmaceuticals SPA.

19 DISCLAIMER